Trump wants to overhaul drug sales. A company tied to his son stands to benefit.

The country’s top drugmakers are set to meet in early December at the Four Seasons hotel in Georgetown with Donald Trump Jr. and senior Trump administration officials that regulate the pharmaceutical industry.

- Annie Linskey & Josh Dawsey

The host: BlinkRx, an online prescription drug delivery company that this year installed Trump Jr. as a board member. The summit will conclude with a dinner at the Executive Branch, the exclusive new club founded by Trump Jr. and his close friends, according to people with knowledge of the event and a copy of the invitation viewed by The Wall Street Journal.

BlinkRx stands to benefit from a shakeup of how patients buy drugs after President Trump urged pharmaceutical companies to sell their medicines directly to consumers. BlinkRx helps drugmakers do exactly that with a service that promises to set up direct-to-patient sales programs in as little as three weeks. TrumpRx, a new government website set to launch in early 2026, would funnel patients to direct-sale sites.

The invitation to the “Future of Pharmaceuticals” summit prompted consternation among some drug-company representatives, who worried that the gathering signaled that the White House wants them to work with the little-known BlinkRx because of its ties to the president's family, according to people familiar with the matter.

It is the latest example of the Trump administration’s policy priorities overlapping with the business dealings of the president and his family.

“BlinkRx is one of many companies in the marketplace that provide these kinds of services to manufacturers,” said Adam J. Fein, the president of Drug Channels Institute, a group that studies the pharmaceutical industry. “What is different is Trump’s son is on the board.”

Drew Hudson, vice president of corporate affairs at BlinkRx, said “no company will be pitching any services” at the December event. And Trump Jr. said in a statement to the Journal that this article amounts to an “innuendo smear” and accused the paper of pursuing the story at the behest of pharmaceutical-industry advertisers.